A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis
Phase of Trial: Phase II/III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Benralizumab (Primary)
- Indications Eosinophilic gastroenteritis
- Focus Therapeutic Use
- 03 Oct 2019 Planned End Date changed from 30 Mar 2021 to 30 Mar 2022.
- 12 Apr 2018 Status changed from not yet recruiting to recruiting.
- 26 Mar 2018 New trial record